Retatrutide weight loss results from Phase 3 testing have captured widespread attention in the obesity medicine community — and for good reason. According to a recently reported analysis of Phase 3 obesity trial data, retatrutide achieved a mean weight loss of approximately 22.6% in a pair of Phase 3 studies, representing a landmark outcome for a medication class that continues to redefine what is clinically achievable in obesity treatment.
It is worth noting, however, that this 22.6% figure — while historic in context — falls somewhat short of the 28.7% mean weight loss recorded in the TRIUMPH-4 Phase 3 trial, which ran for 68 weeks at a 12mg maintenance dose. TRIUMPH-4 represents the highest mean weight loss ever documented in a Phase 3 obesity trial. The variation across trials likely reflects differences in patient populations, titration schedules, trial duration, and study design — all factors that can meaningfully shift outcomes in weight management research.
Retatrutide (LY3437943), developed by Eli Lilly, is a once-weekly subcutaneous injection that works as a triple hormone receptor agonist, simultaneously activating receptors for GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. This mechanism — sometimes called "triple G" in patient community shorthand — distinguishes retatrutide from currently approved single or dual agonists. By engaging all three receptor pathways, retatrutide suppresses appetite, reduces what patient communities often describe as food noise, and increases energy expenditure through glucagon receptor activation.
Yes. According to the reported findings, retatrutide met the primary endpoints of the pair of Phase 3 obesity trials in question. Meeting a primary endpoint in a Phase 3 randomized controlled trial is the fundamental regulatory threshold — it means the drug demonstrated statistically significant and clinically meaningful weight reduction compared to placebo under rigorous trial conditions.
This outcome is consistent with the trajectory established in Phase 2 testing. The published Phase 2 trial (Jastreboff et al., NEJM, 2023; NCT04881760) enrolled 338 adults with a BMI ≥30 or ≥27 with a weight-related comorbidity, excluding those with type 2 diabetes. At 48 weeks, participants receiving the 8mg dose experienced a mean weight loss of approximately 22.8%, while those on 12mg reached approximately 24.2% — compared to roughly 2.1% in the placebo group. Notably, 100% of participants in the 8mg group and 97% in the 12mg group achieved at least 5% weight loss by week 48.
The TRIUMPH-4 trial used a graduated titration schedule: 2mg for weeks 1–4, advancing to 4mg, then 6mg, then 9mg, before reaching 12mg maintenance at week 17 onward. The 68-week duration allowed participants to reach and sustain full therapeutic exposure, which likely contributed to the exceptional 28.7% mean weight loss result.
As of April 2026, peer-reviewed Phase 3 publication is pending, and no New Drug Application (NDA) has yet been filed with the FDA. An approval timeline has not been publicly confirmed.
This is where the clinical picture becomes more nuanced. According to the reported Phase 3 data, the trials did not demonstrate that retatrutide reduces cardiovascular risk. This is an important distinction for clinicians and patients to understand clearly: meeting a weight loss primary endpoint is not the same as proving cardiovascular benefit.
Dedicated cardiovascular outcomes trials (CVOTs) are typically conducted separately and require much larger sample sizes and longer follow-up periods to detect differences in events like heart attack, stroke, and cardiovascular death. The absence of proven cardiovascular benefit at this stage does not imply cardiovascular harm — it means that specific question has not yet been answered by the available Phase 3 data.
That said, Phase 2 data did reveal encouraging cardiometabolic signals. At 24 weeks, participants on the 12mg dose experienced a 34.0% reduction in fasting triglycerides and a 17.3% reduction in total cholesterol compared to placebo. LDL cholesterol declined by 15.6–16.9% in the 8mg groups. Quality of life scores, measured via the SF-36v2, also improved across all active dose groups by week 48. These biomarker improvements are biologically plausible mechanisms through which weight loss medications might eventually demonstrate cardiovascular benefit — but biomarker data alone does not constitute proof of reduced cardiovascular events.
To put retatrutide weight loss results in clinical context, the comparison table below illustrates how approved and investigational agents have performed in their respective pivotal obesity trials. All figures reflect mean percent body weight loss at the highest approved or studied dose in the primary trial population.
| Medication | Mechanism | Trial | Duration | Mean Weight Loss |
|---|---|---|---|---|
| Semaglutide 2.4mg | GLP-1 agonist | STEP-1 | 68 weeks | ~14.9% |
| Tirzepatide 15mg | GLP-1/GIP dual agonist | SURMOUNT-1 | 72 weeks | ~20.9% |
| Retatrutide 12mg (Phase 2) | GLP-1/GIP/glucagon triple agonist | NCT04881760 | 48 weeks | ~24.2% |
| Retatrutide 12mg (Phase 3, reported) | GLP-1/GIP/glucagon triple agonist | Phase 3 pair | Not specified | ~22.6% |
| Retatrutide 12mg (TRIUMPH-4) | GLP-1/GIP/glucagon triple agonist | TRIUMPH-4 | 68 weeks | 28.7% |
The data establish a clear stepwise progression. Each advance in receptor engagement — from single to dual to triple agonism — has corresponded with progressively greater mean weight loss across trial populations. Retatrutide, commonly referred to as reta in patient communities, appears to represent a meaningful step beyond what current approved therapies can achieve. For patients who have not reached their weight loss goals on semaglutide or tirzepatide, or who continue to experience significant food noise despite treatment, the data suggest retatrutide may offer a clinically relevant therapeutic advance.
Safety signals observed in Phase 2 and Phase 3 testing include dose-dependent gastrointestinal side effects — primarily nausea, diarrhea, and vomiting — that typically peak during the titration phase and improve with dose stabilization. A notable adverse event at higher doses is dysesthesia (abnormal skin sensation), reported in 20.9% of 12mg participants in TRIUMPH-4 compared to 0.7% on placebo. Discontinuation rates in TRIUMPH-4 were 18.2% at 12mg versus 4.0% on placebo, and some discontinuations were attributed to what investigators described as perceived excessive weight loss. These are important safety considerations that will factor into eventual regulatory review.
Retatrutide is not yet FDA-approved, and no NDA has been filed as of April 2026. The path from Phase 3 completion to regulatory approval involves additional review processes and timelines that have not been publicly confirmed by Eli Lilly.
For patients and clinicians following this space closely, glp3md.com maintains an active waitlist for retatrutide information updates. Joining the waitlist ensures access to timely, evidence-based clinical updates as Phase 3 data publications, NDA filings, and regulatory milestones emerge. Please note: joining the waitlist does not constitute enrollment in any treatment program, and no promises are made regarding medication availability, prescriptions, or access to retatrutide, which remains an investigational therapy. Visit https://www.glp3md.com to add your name to the list and stay informed as the science continues to evolve.
Join the waitlist for priority access to a prescribing physician when retatrutide receives FDA approval.
Join the WaitlistThis article is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and is not FDA approved as of publication. Clinical data referenced is from publicly available trial publications. Consult a qualified healthcare provider before making any treatment decisions.